Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 14/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307230 | 1.00 | CCR3 (0.55) | CCR3NPC1RAB9AMCHR1CCR5 | |
| SCHEMBL6303694 | 0.91 | CXCR4 (0.46) | CCR3NPC1RAB9AEPHX1 | |
| SCHEMBL6303695 | 0.91 | CXCR4 (0.46) | CCR3NPC1RAB9AEPHX1 | |
| SCHEMBL6305745 | 0.90 | CCR3 (0.62) | CCR3CCR5 | |
| SCHEMBL6305743 | 0.90 | CCR3 (0.62) | CCR3CCR5 | |
| SCHEMBL6312646 | 0.88 | MEN1 (0.51) | CCR3EPHX1 | |
| SCHEMBL6312650 | 0.88 | MEN1 (0.51) | CCR3EPHX1 | |
| SCHEMBL6304099 | 0.87 | RAB9A (0.48) | CCR3NPC1RAB9AMCHR1EPHX1 | |
| SCHEMBL6304095 | 0.87 | RAB9A (0.48) | CCR3NPC1RAB9AMCHR1EPHX1 | |
| SCHEMBL6311625 | 0.86 | CCR3 (0.54) | CCR3CCR5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | disclosed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | CCR3 2/4885NPC1 806/4885RAB9A 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.